Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
OFIX's Cash-to-Debt is ranked higher than
97% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. OFIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OFIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.37 Max: No Debt
Current: No Debt
Equity-to-Asset 0.74
OFIX's Equity-to-Asset is ranked higher than
71% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. OFIX: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
OFIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.7 Max: 0.85
Current: 0.74
0.36
0.85
Interest Coverage 2024.47
OFIX's Interest Coverage is ranked higher than
60% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. OFIX: 2024.47 )
Ranked among companies with meaningful Interest Coverage only.
OFIX' s Interest Coverage Range Over the Past 10 Years
Min: 0.68  Med: 6.72 Max: No Debt
Current: 2024.47
Piotroski F-Score: 6
Altman Z-Score: 7.77
Beneish M-Score: -2.63
WACC vs ROIC
3.33%
-4.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 7.14
OFIX's Operating Margin % is ranked higher than
63% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. OFIX: 7.14 )
Ranked among companies with meaningful Operating Margin % only.
OFIX' s Operating Margin % Range Over the Past 10 Years
Min: -49.44  Med: 4.7 Max: 17.01
Current: 7.14
-49.44
17.01
Net Margin % 0.33
OFIX's Net Margin % is ranked higher than
52% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. OFIX: 0.33 )
Ranked among companies with meaningful Net Margin % only.
OFIX' s Net Margin % Range Over the Past 10 Years
Min: -43.98  Med: 0.02 Max: 9.73
Current: 0.33
-43.98
9.73
ROE % 0.52
OFIX's ROE % is ranked higher than
53% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. OFIX: 0.52 )
Ranked among companies with meaningful ROE % only.
OFIX' s ROE % Range Over the Past 10 Years
Min: -71.87  Med: 0.08 Max: 16.37
Current: 0.52
-71.87
16.37
ROA % 0.38
OFIX's ROA % is ranked higher than
58% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. OFIX: 0.38 )
Ranked among companies with meaningful ROA % only.
OFIX' s ROA % Range Over the Past 10 Years
Min: -31.59  Med: 0.04 Max: 7.45
Current: 0.38
-31.59
7.45
ROC (Joel Greenblatt) % 24.27
OFIX's ROC (Joel Greenblatt) % is ranked higher than
73% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. OFIX: 24.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OFIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -121.91  Med: 13.27 Max: 27.87
Current: 24.27
-121.91
27.87
3-Year Revenue Growth Rate 1.40
OFIX's 3-Year Revenue Growth Rate is ranked lower than
59% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. OFIX: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OFIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 13.7 Max: 28.7
Current: 1.4
-10.5
28.7
3-Year EBITDA Growth Rate 54.00
OFIX's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. OFIX: 54.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OFIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.3 Max: 63.2
Current: 54
0
63.2
GuruFocus has detected 4 Warning Signs with Orthofix International NV OFIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OFIX's 30-Y Financials

Financials (Next Earnings Date: 2018-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

OFIX Guru Trades in Q4 2016

Paul Tudor Jones 29,923 sh (+125.34%)
Jim Simons 745,579 sh (+42.23%)
Chuck Royce 55,700 sh (unchged)
Mario Gabelli 95,425 sh (-1.34%)
Diamond Hill Capital 997,215 sh (-15.26%)
» More
Q1 2017

OFIX Guru Trades in Q1 2017

Chuck Royce Sold Out
Diamond Hill Capital 991,377 sh (-0.59%)
Jim Simons 740,579 sh (-0.67%)
Mario Gabelli 94,625 sh (-0.84%)
Paul Tudor Jones 9,919 sh (-66.85%)
» More
Q2 2017

OFIX Guru Trades in Q2 2017

Mario Gabelli 93,825 sh (-0.85%)
Diamond Hill Capital 979,541 sh (-1.19%)
Jim Simons 455,579 sh (-38.48%)
Paul Tudor Jones 4,469 sh (-54.95%)
» More
Q3 2017

OFIX Guru Trades in Q3 2017

Paul Tudor Jones Sold Out
Mario Gabelli 93,025 sh (-0.85%)
Jim Simons 431,700 sh (-5.24%)
Diamond Hill Capital 608,962 sh (-37.83%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-09-30 Reduce -0.85%$43.05 - $49.89 $ 52.8912%93,025
Mario Gabelli 2017-06-30 Reduce -0.85%$36.4 - $46.6 $ 52.8928%93,825
Mario Gabelli 2017-03-31 Reduce -0.84%$34.47 - $39.91 $ 52.8943%94,625
Mario Gabelli 2016-12-31 Reduce -1.34%$34.56 - $42.01 $ 52.8939%95,425
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113 
Compare:XTER:SBS, SZSE:300642, NAS:XENT, XBRU:IBAB, SZSE:300206, NAS:KTWO, SZSE:300318, NAS:CSII, SZSE:300562, OTCPK:NMRD, SZSE:300326, SZSE:300238, TSE:4548, LSE:CSRT, TSE:6960, HKSE:01302, SZSE:300314, TSE:4549, NYSE:CRY, NAS:AXGN » details
Traded in other countries:OFX.Germany,
Headquarter Location:
Orthofix International NV is a medical device company. It focuses on providing reconstructive and regenerative orthopedic and spine solutions to physicians.

Orthofix International NV is a medical device company. It focuses on providing reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments; BioStim segment is engaged in providing support services for bone growth stimulator devices that enhance bone fusion. The Biologics segment is involved in regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Extremity Fixation segment markets orthopedic products used in fracture repair and deformity correction of bones and the Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. Business activity of the group is functioned through the market of United States.

Ratios

vs
industry
vs
history
PE Ratio 661.16
OFIX's PE Ratio is ranked lower than
92% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. OFIX: 661.16 )
Ranked among companies with meaningful PE Ratio only.
OFIX' s PE Ratio Range Over the Past 10 Years
Min: 10.36  Med: 33.1 Max: 672.78
Current: 661.16
10.36
672.78
Forward PE Ratio 29.15
OFIX's Forward PE Ratio is ranked lower than
60% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. OFIX: 29.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 1763.00
OFIX's PE Ratio without NRI is ranked lower than
92% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. OFIX: 1763.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
OFIX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.36  Med: 29.39 Max: 1794
Current: 1763
10.36
1794
PB Ratio 3.37
OFIX's PB Ratio is ranked lower than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. OFIX: 3.37 )
Ranked among companies with meaningful PB Ratio only.
OFIX' s PB Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.08 Max: 3.44
Current: 3.37
0.77
3.44
PS Ratio 2.25
OFIX's PS Ratio is ranked higher than
64% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. OFIX: 2.25 )
Ranked among companies with meaningful PS Ratio only.
OFIX' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.55 Max: 2.3
Current: 2.25
0.31
2.3
Price-to-Free-Cash-Flow 78.55
OFIX's Price-to-Free-Cash-Flow is ranked lower than
75% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. OFIX: 78.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OFIX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.76  Med: 23.07 Max: 633.66
Current: 78.55
9.76
633.66
Price-to-Operating-Cash-Flow 32.58
OFIX's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. OFIX: 32.58 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OFIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.73  Med: 13.68 Max: 111.83
Current: 32.58
5.73
111.83
EV-to-EBIT 29.99
OFIX's EV-to-EBIT is ranked lower than
57% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. OFIX: 29.99 )
Ranked among companies with meaningful EV-to-EBIT only.
OFIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.7  Med: 22.6 Max: 272.1
Current: 29.99
-37.7
272.1
EV-to-EBITDA 17.80
OFIX's EV-to-EBITDA is ranked lower than
55% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. OFIX: 17.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
OFIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -144.1  Med: 14.8 Max: 769.5
Current: 17.8
-144.1
769.5
EV-to-Revenue 2.12
OFIX's EV-to-Revenue is ranked higher than
70% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. OFIX: 2.12 )
Ranked among companies with meaningful EV-to-Revenue only.
OFIX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 1.6 Max: 3.1
Current: 2.12
0.9
3.1
Current Ratio 2.88
OFIX's Current Ratio is ranked higher than
59% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. OFIX: 2.88 )
Ranked among companies with meaningful Current Ratio only.
OFIX' s Current Ratio Range Over the Past 10 Years
Min: 1.56  Med: 3.4 Max: 5.24
Current: 2.88
1.56
5.24
Quick Ratio 1.80
OFIX's Quick Ratio is ranked lower than
51% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. OFIX: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
OFIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 2.57 Max: 4.2
Current: 1.8
1.13
4.2
Days Inventory 275.83
OFIX's Days Inventory is ranked lower than
81% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. OFIX: 275.83 )
Ranked among companies with meaningful Days Inventory only.
OFIX' s Days Inventory Range Over the Past 10 Years
Min: 222.27  Med: 246.29 Max: 336.86
Current: 275.83
222.27
336.86
Days Sales Outstanding 52.49
OFIX's Days Sales Outstanding is ranked higher than
76% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. OFIX: 52.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
OFIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.53  Med: 79.42 Max: 105.88
Current: 52.49
51.53
105.88
Days Payable 52.52
OFIX's Days Payable is ranked lower than
51% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. OFIX: 52.52 )
Ranked among companies with meaningful Days Payable only.
OFIX' s Days Payable Range Over the Past 10 Years
Min: 48.79  Med: 69.08 Max: 81.8
Current: 52.52
48.79
81.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.50
OFIX's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. OFIX: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OFIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.6  Med: -1.7 Max: 1.2
Current: 0.5
-8.6
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.57
OFIX's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. OFIX: 8.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OFIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 5.27 Max: 235
Current: 8.57
2.2
235
Price-to-Tangible-Book 4.34
OFIX's Price-to-Tangible-Book is ranked higher than
51% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. OFIX: 4.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OFIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 4.12 Max: 110.32
Current: 4.34
1.48
110.32
Price-to-Intrinsic-Value-Projected-FCF 2.34
OFIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. OFIX: 2.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OFIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.45 Max: 23.25
Current: 2.34
0.55
23.25
Price-to-Median-PS-Value 1.46
OFIX's Price-to-Median-PS-Value is ranked lower than
67% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. OFIX: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OFIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.23 Max: 2.98
Current: 1.46
0.33
2.98
Price-to-Graham-Number 18.43
OFIX's Price-to-Graham-Number is ranked lower than
74% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. OFIX: 18.43 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OFIX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.88  Med: 2.02 Max: 18.75
Current: 18.43
0.88
18.75
Earnings Yield (Greenblatt) % 3.35
OFIX's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. OFIX: 3.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OFIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -62.8  Med: 3 Max: 13.6
Current: 3.35
-62.8
13.6
Forward Rate of Return (Yacktman) % 2.36
OFIX's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. OFIX: 2.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OFIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -41.7  Med: 3.6 Max: 29.3
Current: 2.36
-41.7
29.3

More Statistics

Revenue (TTM) (Mil) $425.46
EPS (TTM) $ 0.08
Beta0.16
Short Percentage of Float4.61%
52-Week Range $32.51 - 54.33
Shares Outstanding (Mil)18.23

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 430 452 474 498
EPS ($) 1.58 1.82 2.00 2.20
EPS without NRI ($) 1.58 1.82 2.00 2.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.10%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}